Latest Breaking News On - Roger hajjar - Page 1 : comparemela.com

Longeveron Announces Board of Directors Planned Transitions

AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)

GenePHIT, which is now enrolling, will study AB-1002 in adults with NYHA Class III Heart Failure and non-ischemic cardiomyopathy 

A gene therapy treatment for rare SMA syndrome costs $2 million dollars. What happens if it doesn't cure the disease?

Spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy globally.

What happens when a $2 million gene therapy is not enough

(This Aug. 12 story has been corrected to state that ICER's final analysis was that Zolgensma was cost effective at a price of $1.1 million to $1.9

What Happens When a $2 Million Gene Therapy Is Not Enough

Baby Ben Kutschke was diagnosed at 3 months with spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy globally.